Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study

被引：0
|
作者：
Yuichiro Kikawa
Takeshi Kotake
Shigeru Tsuyuki
Yookija Kang
Sachiko Takahara
Yuri Fujimoto
Hiroyasu Yamashiro
Hiroshi Yoshibayashi
Masahiro Takada
Rie Yasuoka
Katsuhiko Nakatsukasa
Kazuhiko Yamagami
Hirofumi Suwa
Toshitaka Okuno
Ichiro Nakayama
Tatsushi Kato
Nobuko Ogura
Yoshio Moriguchi
Hiroshi Ishiguro
Tatsuo Kagimura
Tetsuya Taguchi
Tomoharu Sugie
Masakazu Toi
机构：
[1] Kansai Medical University,Department of Breast Surgery
[2] Kobe City Medical Center General Hospital,Department of Breast Surgery
[3] Kyoto University Graduate School of Medicine,Department of Breast Surgery
[4] Kansai Electric Power Hospital,Department of Breast Surgery
[5] Osaka Red Cross Hospital,Department of Breast Surgery
[6] Kitano Hospital,Department of Breast Surgery, Tazuke Kofukai Medical Research Institute
[7] Tenri Hospital,Department of Breast Surgery
[8] Wakayama Breast Clinic,Department of Endocrine and Breast Surgery
[9] Kyoto Prefectural University of Medicine,Department of Breast Surgery
[10] Shinko Hospital,Department of Breast Surgery
[11] Hyogo Prefectural Amagasaki General Medical Center,Department of Breast Surgery
[12] Kobe City Nishi-Kobe Medical Center,Department of Breast Surgery
[13] Kyoto Min-Iren Chuo Hospital,Department of Breast Surgery, Yamato Takada Municipal Hospital
[14] Yamatotakada-city,Department of Breast Surgery
[15] Kyoto City Hospital,Breast Oncology Service
[16] Saitama Medical University International Medical Center,Translational Research Center for Medical Innovation
[17] Foundation for Biomedical Research and Innovation at Kobe,undefined
来源：
Breast Cancer | 2022年 / 29卷
关键词：
Breast cancer; Metastasis; Eribulin; Chemotherapy sequence; Real world;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：796 / 807
页数：11
相关论文
共 22 条
  • [21] Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
    Kim, Ji-Yeon
    Park, Seri
    Im, Seock-Ah
    Kim, Sung-Bae
    Sohn, Joohyuk
    Lee, Keun Seok
    Chae, Yee Soo
    Lee, Ki Hyeong
    Kim, Jee Hyun
    Im, Young-Hyuck
    Kim, Tae-Yong
    Lee, Kyung-Hun
    Ahn, Jin-Hee
    Kim, Gun Min
    Park, In Hae
    Lee, Soo Jung
    Han, Hye Sook
    Kim, Se Hyun
    Jung, Kyung Hae
    Park, Yeon Hee
    CANCER COMMUNICATIONS, 2019, 39
  • [22] Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) (vol 21, 391, 2020)
    Yamashita, Toshinari
    Masuda, Norikazu
    Saji, Shigehira
    Araki, Kazuhiro
    Ito, Yoshinori
    Takano, Toshimi
    Takahashi, Masato
    Tsurutani, Junji
    Koizumi, Kei
    Kitada, Masahiro
    Kojima, Yasuyuki
    Sagara, Yasuaki
    Tada, Hiroshi
    Iwasa, Tsutomu
    Kadoya, Takayuki
    Iwatani, Tsuguo
    Hasegawa, Hiroki
    Morita, Satoshi
    Ohno, Shinji
    TRIALS, 2020, 21 (01)
123